The global cell free expression market size is estimated to grow from USD 346 million in the current year to USD 627 million by 2035, at a CAGR of 6.8% during the forecast period, till 2035.
In general, cell-free protein expression systems provide numerous benefits compared to the conventional method, such as the capacity to generate a wide variety of target molecules by modifying components tailored for their synthesis, increased yield, reduced development periods, and lower production costs. Protein expression without cells is conducted using cell-free systems or commercially available cell-free expression kits.
Cell-free protein expression systems have shown the ability to facilitate the synthesis of various complex proteins, such as toxic proteins, membrane proteins, and other proteins modified post-translationally, which are often difficult to produce with cell-based systems. With the increasing need for biologic products, cell-free expression has emerged as a major sector of interest for those involved in the biopharmaceutical sector.
Cell Free Systems Market
The market sizing and opportunity analysis has been segmented across the following parameters:
Type of Cell Free System
- Crude Cell Lysate-Based Systems
- Reconstituted Systems
Type of Host Organism
- Microbial Cell Free Expression Systems
- Mammalian Cell Free Expression Systems
- Plant-based Cell Free Expression Systems
- Other Cell Free Expression Systems
Type of Expression Method
- Coupled Transcription and Translation Method
- Translation Method
End-user
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Other End-Users
Geographical Regions
- North America
- Europe
- Asia-Pacific
- Rest of the World
CELL FREE EXPRESSION SYSTEMS MARKET: GROWTH AND TRENDS
Over the years cell-free expression systems have become a viable alternative to the traditional cell-based protein production method. Traditional biomanufacturing is recognized as a complicated procedure that necessitates living cells and particular environments to sustain adequate homeostasis for cell proliferation. Additionally, cell-based biomanufacturing presents fundamental constraints on the efficient generation of biologics. Alternatively, cell-free protein expression systems are in vitro platforms that utilize the transcription and translation mechanisms of living cells, achieved through cell lysates, to produce different kinds of biologics, especially proteins. Several players have developed kits for the cell-free expression of enzymes, which are a category of proteins. Notably, Enzymit, a bioproduction company, employs cell-free technology to produce affordable enzymes.In general, cell-free protein expression systems provide numerous benefits compared to the conventional method, such as the capacity to generate a wide variety of target molecules by modifying components tailored for their synthesis, increased yield, reduced development periods, and lower production costs. Protein expression without cells is conducted using cell-free systems or commercially available cell-free expression kits.
Cell-free protein expression systems have shown the ability to facilitate the synthesis of various complex proteins, such as toxic proteins, membrane proteins, and other proteins modified post-translationally, which are often difficult to produce with cell-based systems. With the increasing need for biologic products, cell-free expression has emerged as a major sector of interest for those involved in the biopharmaceutical sector.
CELL FREE PROTEIN EXPRESSION MARKET: KEY INSIGHTS
The report delves into the current state of the cell free protein expression system market and identifies potential growth opportunities within industry. Some key findings from the report include:
- Presently, more than 35 players across the globe claim to offer cell free expression services for synthesis of a variety of biomolecules.
- The current market landscape is fragmented, featuring the presence of both new entrants and established players catering to needs of various industries; majority of these players are based in the US.
- In pursuit of building a competitive edge in this field, stakeholders are actively upgrading their existing capabilities and adding new competencies in order to enhance their respective service portfolios.
- More than 90 cell free expression kits are currently available in the market for the synthesis of different types of biomolecules; these kits utilize different types of host organisms for cell free expression.
- Cell free expression kits utilize a range of cell free expression systems for the synthesis of different types of biologics; majority of these include proteins, followed by oligonucleotides and others.
- Owing to the rise in demand for difficult to express biomolecules, the requirement of cell free expression is increasing, prompting the stakeholders to upgrade their product offerings.
- Since 2015, more than 430 patents have been filed / granted by various stakeholders in order to protect the intellectual property generated within this field.
- The growing interest is evident from the rise in partnership activity; product development agreements have been the most common.
- Several investors having realized the opportunity within this domain, have invested more than USD 8 billion across various funding rounds in the past six years.
- The cell free expression market is likely to grow at a CAGR of 6.8%, till 2035; this opportunity is expected to be well distributed across different types of cell free systems, host organisms and expression methods.
- Growth in this domain is anticipated to be primarily driven by the rising demand for biologics; North America is expected to capture larger share (over 50%) of the market by 2035.
CELL FREE PROTEIN EXPRESSION MARKET: KEY SEGMENTS
Crude Cell Lysate-based Systems Capture Majority of the Current Cell Free Systems Market Share
In terms of type of cell-free system, the market is segmented across Crude Cell Lysate-Based Systems and Reconstituted Systems. Majority of the market share is captured by Crude Cell Lysate-based Systems (90%) and this trend is unlikely to change in the future. Reconstituted systems segment is likely to grow at a CAGR of 10.3% during the forecast period.Currently, Microbial Cell-free Expression Systems Hold the Highest Cell Free Systems Market Share
In terms of type of cell-free expression system, the cell free systems market is segmented across microbial, mammalian, plant-based and other cell-free expression systems. Around 60% of the market share is likely to be captured by microbial cell free expression systems, followed by mammalian cell free expression systems (25%) and plant-based cell free expression systems (10%).Pharmaceutical and Biotechnology Companies are Anticipated to Hold Maximum Cell Free Systems Market Share in the Future
In terms of end-users, the cell free system market is segmented across academic and research institutes, pharmaceutical and biotechnology companies, and other end-users. Majority of the market share is likely to held by pharmaceutical and biotechnology companies (65%), growing at a CAGR of 7.9%.North America is Likely to Propel the Cell Free Systems Market in the Future
In terms of geographical regions, the single-cell sequencing market is segmented across North America, Europe, Asia-Pacific and Rest of the World. Over 50% of the market share is captured by North America, followed by Europe (31%) and Asia-Pacific (12%).Example Players in the Cell Free Protein Expression Market
- BioLinker
- Biotechrabbit
- CellFreeSciences
- Creative Biolabs
- CUSABIO
- Daicel Arbor Biosciences
- LenioBio
- Promega
- Thermo Fisher Scientific
- Touchlight
CELL FREE PROTEIN EXPRESSION SYSTEMS MARKET: RESEARCH COVERAGE
- Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cell free protein systems market, focusing on key market segments, including [A] type of cell free system, [B] type of host mechanism, [C] type of expression method, [D] end-user, and [E] key geographical regions.
- Market Landscape 1: A detailed assessment of cell free protein expression service providers, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of cell free service(s) offered, [E] type of associated service(s) offered, [F] type of host organism, [G] type of product(s) synthesized, [H] scale of operation and [I] type of industry served.
- Market Landscape 2: A detailed assessment of the current market landscape of cell free protein expression kits, based on several relevant parameters, such as [A] type of cell free system, [B] type of host organism, [C] type of expression method, [D] type of product(s) synthesized, [E] type of template(s) used, [F] type of compatible promoter(s), [G] type of reaction format, [H] year of establishment, [I] company size (in terms of employee count), [J] location of headquarters and [K] leading players.
- Company Competitiveness Analysis: A comprehensive competitive analysis of cell free expression service providers, examining factors, such as [A] supplier strength and [B] service strength.
- Product Competitiveness Analysis: A product competitiveness analysis of cell free expression kits based on various relevant parameters, namely [A] developer power and [B] product competitiveness.
- Company Profiles: In-depth profiles of prominent players engaged in this domain, that are currently involved in cell free systems market, focusing on [A] year of establishment, [B] location of headquarters, [C] cell free expression service portfolio, [D] recent developments and [E] an informed future outlook.
- Partnerships and Collaborations An insightful analysis of the partnerships and collaborations inked between stakeholders engaged in the cell free systems market based on various relevant parameters, including [A] year of partnership, [B] type of partnership, [C] type of partner and [D] most active players.
- Funding and Investment Analysis: A comprehensive examination of various funding and investments raised by developers, based on relevant parameters, including [A] such as year of funding, [B] amount invested [C] type of funding, [D] regional distribution, and [E] most active players.
- Patent Analysis: An in-depth analysis of various patents that have been filed / granted for cell free systems, taking into consideration parameters, such as [A] publication year, [B] type of patent, [C] application year, [D] patent jurisdiction, [E] leading individual assignees.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How many companies are currently engaged in this market?
- Which are the leading companies in this market?
- What is the current global capacity of developers?
- What factors are likely to influence the evolution of this market?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
REASONS TO BUY THIS REPORT
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
ADDITIONAL BENEFITS
- Complimentary PPT Insights Packs
- Complimentary Excel Data Packs Covering All Analytical Modules
- Up to 15% Complimentary Content Customization
- In-Depth Report Walkthrough with the Research Team
- Complimentary Report Update if the Report is 6+ Months Old
Table of Contents
1. PREFACE
3. INTRODUCTION
4. MARKET LANDSCAPE: CELL FREE EXPRESSION SERVICE PROVIDERS
5. MARKET LANDSCAPE: CELL FREE EXPRESSION KITS
6. CELL FREE EXPRESSION SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
7. CELL FREE EXPRESSION KITS: PRODUCT COMPETITIVENESS ANALYSIS
8. COMPANY PROFILES: CELL FREE EXPRESSION SERVICE PROVIDERS
9. COMPANY PROFILES: CELL FREE EXPRESSION KIT PROVIDERS
10. PARTNERSHIPS AND COLLABORATIONS
11. FUNDING AND INVESTMENT ANALYSIS
12. PATENT ANALYSIS
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14. EXECUTIVE INSIGHTS
LIST OF FIGURES
LIST OF TABLES
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abnova
- AMSBIO
- ArchiMed
- AskBio
- Astellas Pharma
- Avalon GloboCare
- Avantor
- Bayer
- BigHat Biosciences
- BioComber
- BioLinker
- Bioneer
- BioNova Pharmaceuticals
- biotechrabbit
- Brigham Young University
- Cambridge Bioscience
- Cancer Research UK
- CD Biosynsis
- CellFree Sciences
- Cornell University
- CortecNet
- Corteva Agriscience
- Creative Biogene
- Creative Biolabs
- Creative BioMart
- Creative Biostructure
- Creative Diagnostics
- CSO (Costruzione Strumenti Oftalmici)
- Cube Biotech
- CUSABIO
- Daicel Arbor Biosciences
- Debut Biotech
- E Ink
- EpiVax
- Epynext Therapeutics
- Excellgen
- Fraunhofer GES Forschung
- Fraunhofer Institute for Cell Therapy and Immunology, Department of Bioanalytics and Bioprocesses (IZI-BB)
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME
- Frugi Biotechnology
- GeneCopoeia
- GeneFrontier
- General Biosystems
- Generation Bio
- Genosphere Biotechnologies
- GenScript
- Germains Seed Technology
- Ginkgo Bioworks
- GMExpression
- GreenLight Biosciences
- IAVI
- iBody
- Imperial College London
- Insempra
- Instruct-ERIC
- Integrated Structural Biology Grenoble
- Janssen Biotech
- Jena Bioscience
- KangMa Healthcode
- KanPro Research
- Kishida Chemical
- LanzaTech
- LenioBio
- Liberum Biotech
- Lifeasible
- Lonza
- Merck
- Moderna
- National Institutes of Health (NIH)
- National Resilience
- Nature's Toolbox (NTx)
- New England Biolabs
- NMR-Bio
- Northwestern University
- Nuclera
- NUProtein
- Odimma Therapeutics
- OpenPlant
- OriCiro Genomics
- PEACCEL
- Pfizer
- Profacgen
- Progeneer
- Promega
- ProteinExpress
- Queensland University of Technology
- RD-BIOTECH
- Riken
- RiNova
- Samsung BioLogics
- Serum Institute of India
- Sigma-Aldrich (aquired by Merck)
- Silk Renaissance
- Stemloop
- Stonehaven Incubate
- Sutro Biopharma
- SwiftScale Biologics (aquired by National Resilience)
- Synthelis
- Takara Bio
- Tasly Biopharmaceuticals
- The Australian National University
- The Leukemia & Lymphoma Society
- The University of Notre Dame
- The University of Queensland
- The University of Tokyo
- Thermo Fisher Scientific
- Tierra Biosciences
- Tokyo Institute of Technology
- Touchlight
- Trans Chromosomics
- UNAPera
- University of Gothenberg
- University of Natural Resources and Life Sciences (BOKU)
- University of Southampton
- US Army
- Vanderbilt University
- Vaxcyte
- Vectorial Synthesis Technologies
- Versameb
- Voyager Therapeutics
- Yale University
- Zymtronix
Methodology
LOADING...
